Table 5 Classifier performance on additional RA test cohorts
From: Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis
Data set | Treatment | Blood sample | Patient breakdown | AUROC(95 % CI) | Specificity(95 % CI) | Sensitivity(95 % CI) | Precision(95 % CI) | Likelihood ratio(95 % CI) |
|---|---|---|---|---|---|---|---|---|
GSE42296 | Infliximab | PBMCs | 13 NR, 6 R | 74 %(51-98 %) | 100 %(42-100 %) | 31 %(9-61 %) | 100 %(28-100 %) | ∞(N/A) |
GSE3592 | Infliximab | PBMCs | 7 NR, 6 R | 55 %(19-90 %) | 67 %(22-96 %) | 14 %(0-58 %) | 33 %(1-91 %) | 0.43(0.1-3.6) |
GSE33377 | Adalimumab | Whole blood | 11 NR, 4 R | 61 %(22-100 %) | 100 %(28-100 %) | 18 %(2-52 %) | 100 %(9-100 %) | ∞(N/A) |
GSE11827 | Anakinra | PBMCs | 7 NR, 7 R | 29 %(0-65 %) | 100 %(47-100 %) | 14 %(0-58 %) | 100 %(1-100 %) | ∞(N/A) |
GSE25160 | Tocilizumab | PBMCs | 4 NR, 9 R | 50 %(9-91 %) | 100 %(47-100 %) | 25 %(1-81 %) | 25 %(1-81 %) | 0.75(0.1-5.2) |
GSE37107 | Rituximab | Whole blood | 6 NR, 8 R | 33 %(0-72 %) | 75 %(35-97 %) | 33 %(4-78 %) | 50 %(7-93 %) | 1.33(0.3-6.9) |